-
EP3275899
European procedure
Extract from the Register of European Patents
EP About this file: EP3275899
| EP3275899 - OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 02.07.2021 Database last updated on 11.04.2026 | |
| Former | The patent has been granted Status updated on 24.07.2020 | ||
| Former | Grant of patent is intended Status updated on 19.03.2020 | ||
| Former | Examination is in progress Status updated on 08.03.2019 | ||
| Former | Request for examination was made Status updated on 27.07.2018 | ||
| Former | The application has been published Status updated on 29.12.2017 | Most recent event Tooltip | 02.07.2021 | No opposition filed within time limit | published on 04.08.2021 [2021/31] | Applicant(s) | For all designated states Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543 / US | [2020/35] |
| Former [2018/05] | For all designated states Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543 / US | Inventor(s) | 01 /
LONBERG, Nils c/o Bristol-Myers Squibb Company 700 Bay Road Redwood City, CA 94063 / US | 02 /
SRINIVASAN, Mohan c/o Bristol-Myers Squibb Company 700 Bay Road Redwood City, CA 94063 / US | [2018/05] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2020/35] |
| Former [2018/05] | Reitstötter Kinzebach Patentanwälte Sternwartstrasse 4 81679 München / DE | Application number, filing date | 17177885.5 | 02.07.2013 | [2018/05] | Priority number, date | US201261667058P | 02.07.2012 Original published format: US 201261667058 P | [2018/05] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3275899 | Date: | 31.01.2018 | Language: | EN | [2018/05] | Type: | B1 Patent specification | No.: | EP3275899 | Date: | 26.08.2020 | Language: | EN | [2020/35] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 17.11.2017 | Classification | IPC: | C07K16/28 | [2018/05] | CPC: |
C07K16/2803 (EP,EA,KR,US);
A61K39/3955 (EA,US);
A61K45/06 (EP,EA,US);
A61K47/6849 (EA,KR,US);
A61P31/12 (EP,EA,KR);
A61P35/00 (EP,EA);
A61P37/02 (EP,EA);
A61P37/04 (EP,EA);
C07K16/18 (EA,US);
C07K16/28 (EA,US);
C07K16/2818 (EA,US);
C07K16/2827 (EA,US);
A61K2039/505 (KR);
A61K2039/507 (EA,US);
A61K39/39558 (EA,US);
C07K16/3061 (EA,US);
C07K2317/14 (EA,US);
C07K2317/21 (EP,EA,US);
C07K2317/24 (KR);
C07K2317/565 (EP,EA,US);
C07K2317/75 (EA,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/35] |
| Former [2018/05] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | OPTIMIERUNG VON ANTIKÖRPERN ZUR BINDUNG DES LYMPHOZYTENAKTIVIERUNGSGENS 3 (LAG-3) UND VERWENDUNGEN DAVON | [2018/05] | English: | OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF | [2018/05] | French: | OPTIMISATION DES ANTICORPS SE LIANT À L'ACTIVATION DES LYMPHOCYTES GÈNE-3 (LAG-3) ET LEURS UTILISATIONS | [2018/05] | Examination procedure | 26.06.2017 | Date on which the examining division has become responsible | 20.07.2018 | Amendment by applicant (claims and/or description) | 20.07.2018 | Examination requested [2018/35] | 13.03.2019 | Despatch of a communication from the examining division (Time limit: M04) | 12.07.2019 | Reply to a communication from the examining division | 20.03.2020 | Communication of intention to grant the patent | 21.07.2020 | Fee for grant paid | 21.07.2020 | Fee for publishing/printing paid | 21.07.2020 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP13737946.7 / EP2867258 | Divisional application(s) | EP20192145.9 / EP3795592 | EP24188894.0 / EP4553086 | EP25179856.7 | Opposition(s) | 27.05.2021 | No opposition filed within time limit [2021/31] | Fees paid | Renewal fee | 26.06.2017 | Renewal fee patent year 03 | 26.06.2017 | Renewal fee patent year 04 | 26.06.2017 | Renewal fee patent year 05 | 11.07.2018 | Renewal fee patent year 06 | 15.07.2019 | Renewal fee patent year 07 | 14.07.2020 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A] WO2010019570 (MEDAREX INC et al.) | [A] WO2012054438 (SCHERING CORP et al.) | [A] CHELIUS DIRK ET AL: "Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies", ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 77, no. 18, 15 September 2005 (2005-09-15), pages 6004 - 6011, XP002407962, ISSN: 0003-2700, DOI: 10.1021/AC050672D DOI: http://dx.doi.org/10.1021/ac050672d | [AD] TSAI P K ET AL: "ORIGIN OF THE ISOELECTRIC HETEROGENEITY OF MONOCLONAL IMMUNOGLOBULIN H1B4", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS, NEW YORK, NY, US, vol. 10, no. 11, 1 November 1993 (1993-11-01), pages 1580 - 1586, XP009020338, ISSN: 0724-8741, DOI: 10.1023/A:1018912417607 DOI: http://dx.doi.org/10.1023/A:1018912417607 | [AD] KROON D ET AL: "Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS, NEW YORK, NY, US, vol. 9, no. 11, 1 November 1992 (1992-11-01), pages 1386 - 1393, XP002079908, ISSN: 0724-8741, DOI: 10.1023/A:1015894409623 DOI: http://dx.doi.org/10.1023/A:1015894409623 | by applicant | US2011150892 | US6951646 | US6914128 | US6090382 | US6818216 | US6156313 | US6827925 | US5833943 | US5762905 | US5760185 | US5225539 | US5530101 | US5585089 | US5693762 | US6180370 | US2003153043 | US5677425 | US6165745 | US6277375 | US5869046 | US6121022 | US5624821 | US5648260 | US6194551 | WO9429351 | WO0042072 | US5714350 | US6350861 | US2004110704 | EP1176195 | WO03035835 | WO2006089231 | WO9954342 | EP0154316 | EP0401384 | US4816567 | US5545806 | US5569825 | US5625126 | US5633425 | US5789650 | US5877397 | US5661016 | US5814318 | US5874299 | US5770429 | US5545807 | WO9203918 | WO9312227 | WO9425585 | WO9713852 | WO9824884 | WO9945962 | WO0114424 | WO0243478 | US5939598 | US6075181 | US6114598 | US6150584 | US6162963 | WO02092812 | US5223409 | US5403484 | US5571698 | US5427908 | US5580717 | US5969108 | US6172197 | US5885793 | US6521404 | US6544731 | US6555313 | US6582915 | US6593081 | US5476996 | US5698767 | US6794132 | US4399216 | US4634665 | US5179017 | WO8704462 | WO8901036 | EP0338841 | US7087600 | US6989452 | US7129261 | WO02096910 | WO2007038658 | WO2007051081 | WO2007059404 | WO2008083312 | WO2008103693 | US2006024317 | US2006004081 | US2006247295 | US5399163 | US5383851 | US5312335 | US5064413 | US4941880 | US4790824 | US4596556 | US4487603 | US4486194 | US4447233 | US4447224 | US4439196 | US4475196 | US4522811 | US5374548 | US5416016 | US5399331 | US5922845 | US5837243 | US5811097 | WO9842752 | WO0037504 | US6207156 | WO2006121168 | WO2008156712 | WO2010027423 | WO2010027827 | WO2010027828 | WO2010098788 | WO2007005874 | WO2010077634 | WO2011066389 | WO2009045957 | WO2009073533 | WO2009073546 | WO2009054863 | SWANN ET AL., CURR OPINION IMMUOL, vol. 20, 2008, pages 493 - 499 | TSAI ET AL., PHARM RES, vol. 10, no. 11, 1993, pages 1580 | PHARM RES, vol. 9, no. 11, 1992, pages 1386,1389 | CACIA ET AL., J. CHROMATOGR., vol. 634, 1993, pages 229 - 239 | TESHIMA ET AL., BIOCHEMISTRY, vol. 30, 1991, pages 3916 - 3922 | KRISHNAMURTHY R; MANNING MC, CURR PHARM BIOTECHNOL, vol. 3, 2002, pages 361 - 71 | CHEN ET AL., PHARM RES, vol. 20, 2003, pages 1952 - 60 | GHIRLANDO ET AL., IMMUNOL LETT, vol. 68, 1999, pages 47 - 52 | MURRAY ET AL., J. CHROMATOGR SCI, vol. 40, 2002, pages 343 - 9 | ALEXANDER AJ; HUGHES DE, ANAL CHEM, vol. 67, 1995, pages 3626 - 32 | ANGAL ET AL., MOL. IMMUNOL., vol. 30, 1993, pages 105 - 108 | KABAT ET AL.: "Sequences of Proteins of Immunological Interest, 5th ed.", 1991, NIH PUBLICATION NO. 91-3242 | WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546 | BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426 | HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883 | KLIMKA ET AL., BRITISH J. OF CANCER, vol. 83, no. 2, 2000, pages 252 - 260 | BEIBOER ET AL., J. MOL. BIOL., vol. 296, 2000, pages 833 - 849 | RADER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 95, 1998, pages 8910 - 8915 | BARBAS ET AL., J. AM. CHEM. SOC., vol. 116, 1994, pages 2161 - 2162 | BARBAS ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 92, 1995, pages 2529 - 2533 | DITZEL ET AL., J. IMMUNOL., vol. 157, 1996, pages 739 - 749 | BEREZOV ET AL., BIAJOURNAL 8:SCIENTIFIC REVIEW 8, 2001 | IGARASHI ET AL., J. BIOCHEM (TOKYO), vol. 117, 1995, pages 452 - 7 | BOURGEOIS ET AL., J. VIROL, vol. 72, 1998, pages 807 - 10 | LEVI ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 4374 - 8 | POLYMENIS; STOLLER, J. IMMUNOL., vol. 152, 1994, pages 5218 - 5329 | XU; DAVIS, IMMUNITY, vol. 13, 2000, pages 37 - 45 | BRUMMELL ET AL., BIOCHEM, vol. 32, 1993, pages 1180 - 8 | DE WILDT ET AL., PROT. ENG., vol. 10, 1997, pages 835 - 41 | KOMISSAROV ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 26864 - 26870 | HALL ET AL., J. IMMUNOL., vol. 149, 1992, pages 1605 - 12 | KELLEY; O'CONNELL, BIOCHEM., vol. 32, 1993, pages 6862 - 35 | ADIB-CONQUY ET AL., INT. IMMUNOL., vol. 10, 1998, pages 341 - 6 | BEERS ET AL., CLIN. CAN. RES., vol. 6, 2000, pages 2835 - 43 | RIECHMANN ET AL., NATURE, vol. 332, 1998, pages 323 - 327 | JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525 | QUEEN ET AL., PROC. NATL. ACAD. SEE. U.S.A., vol. 86, 1989, pages 10029 - 10033 | TOMLINSON ET AL.: "The Repertoire of Human Germline V Sequences Reveals about Fifty Groups of V Segments with Different Hypervariable Loops", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7 DOI: http://dx.doi.org/10.1016/0022-2836(92)90223-7 | COX ET AL.: "A Directory of Human Germ-line V Segments Reveals a Strong Bias in their Usage", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409 DOI: http://dx.doi.org/10.1002/eji.1830240409 | SHIELDS ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604 | YAMANE-OHNUKI ET AL., BIOTECHNOL BIOENG, vol. 87, 2004, pages 614 - 22 | SHIELDS ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740 | UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180 | TARENTINO ET AL., BIOCHEM., vol. 14, 1975, pages 5516 - 23 | MARSHALL ET AL., ANNU REV BIOCHEM, vol. 41, 1972, pages 673 - 702 | GALA; MORRISON, J IMMUNOL, vol. 172, 2004, pages 5489 - 94 | WALLICK ET AL., JEXP MED, vol. 168, 1988, pages 1099 - 109 | SPIRO, GLYCOBIOLOGY, vol. 12, 2002, pages 43R - 56R | PAREKH ET AL., NATURE, vol. 316, 1985, pages 452 - 7 | MIMURA ET AL., MOL IMMUNOL, vol. 37, 2000, pages 697 - 706 | AUSUBEL, ET AL.: "Current Protocols in Molecular Biology", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE | MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554 | KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 | LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859 | LONBERG: "Handbook of Experimental Pharmacology", vol. 113, 1994, pages: 49 - 101 | LONBERG, N.; HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93 | HARDING; LONBERG, ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546 | TAYLOR ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295 | CHEN ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656 | TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 3720 - 3724 | CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123 | CHEN ET AL., EMBO J., vol. 12, 1993, pages 821 - 830 | TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920 | TAYLOR ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591 | FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851 | TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727 | KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894 | HARLOW; LANE: "Antibodies, A Laboratory Manual", 1988, COLD SPRING HARBOR PUBLICATIONS | TAKEBE ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472 | URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220 | R. J. KAUFMAN; P. A. SHARP, J. MOL. BIOL., vol. 159, 1982, pages 601 - 621 | KUFER ET AL., TRENDS IN BIOTECHNOLOGY, vol. 22, no. 5, 2004, pages 238 - 244 | CAO; SURESH, BIOCONJUGATE CHEMISTRY, vol. 9, no. 6, 1998, pages 635 - 644 | VAN SPRIEL ET AL., IMMUNOLOGY TODAY, vol. 21, no. 8, 2000, pages 391 - 397 | GENNARO: "Remington: The Science and Practice of Pharmacy, 20th ed.", 2003, LIPPINCOTT WILLIAMS & WILKINS | J.R. ROBINSON: "Sustained and Controlled Release Drug Delivery Systems", 1978, MARCEL DEKKER, INC. | V.V. RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685 | UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, 1988, pages 1038 | BLOEMAN ET AL., FEBS LETT., vol. 357, 1995, pages 140 | M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180 | BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134 | SCHREIER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 9090 | KEINANEN; LAUKKANEN, FEBS LETT., vol. 346, 1994, pages 123 | KILLION; FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273 | IWAI ET AL., INT. IMMUNOL., vol. 17, 2005, pages 133 - 144 | HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28 | ROSENBERG, S.: "Development of Cancer Vaccines", 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 60 - 62 | LOGOTHETIS, C., 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 300 - 302 | KHAYAT, D., 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 414 - 428 | FOON, K, 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 730 - 738 | DEVITA ET AL.: "Cancer: Principles and Practice of Oncology, 5th ed.", 1997, article RESTIFO, N.; SZNOL, M. ET AL.: "Cancer Vaccines (ch. 61)", pages: 3023 - 3043 | DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43 | ROSENBERG, SA, IMMUNITY, vol. 10, 1999, pages 281 - 7 | KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013 | SUOT; SRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588 | TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120 | NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332 | KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336 | MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304 | KEHRL ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050 | HOWARD; O'GARRA, IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200 | HAHNE ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365 | RIDGE ET AL., NATURE, vol. 393, 1998, pages 474 - 478 | ITO ET AL., IMMUNOBIOLOGY, vol. 201, no. 5, 2000, pages 527 - 40 | WEINBERG ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169 | MELERO ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685 | HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 262 - 266 | GREENBERG; RIDDELL, SCIENCE, vol. 285, 1999, pages 546 - 51 | HOLLIGER, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448 | POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123 | VAN ELSAS ET AL., J. EXP. MED., vol. 194, 2001, pages 481 - 489 | OVERWIJK ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 96, 1999, pages 2982 - 2987 | ROSENBERG; WHITE, J. IMMUNOTHER EMPHASIS TUMOR IMMUNOL, vol. 19, no. 1, 1996, pages 81 - 4 | SCHENK ET AL., NATURE, vol. 400, 1999, pages 173 - 177 | HURWITZ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071 | CAMACHO ET AL., J. CLIN. ONCOLOGY, vol. 22, no. 145, 2004 | MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304 |